Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its second quarter 2009 financial results before the market opens on Thursday, August 13, 2009, and host a conference call shortly thereafter at 8:30 AM (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, Executive Vice President and Chief Financial Officer, will host the call.

Interested parties may participate in the conference call by dialing 877-941-1467 (US), or 480-629-9677 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 PM Eastern Time on August 27, by dialing 800-406-7325 (US), or 303 590 3030 (International), and entering reservation #4134644. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares website at www.antarespharma.com.

About Antares Pharma (www.antarespharma.com)

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection technology platforms, including VibexTM disposable pressure-assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors, and disposable multi-use pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA-approved products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.